Adrenergic alpha-Antagonists Drug Therapy Combination Humans Lower Urinary Tract Symptoms Male Middle Aged Phosphodiesterase Inhibitors Prostatic Hyperplasia Randomized Controlled Trials as Topic

Adrenergic alpha-Antagonists Benzilates Drug Combinations Ethamsylate Humans Indoles Lower Urinary Tract Symptoms Male Naphthalenes Piperazines Plant Extracts Prostatic Hyperplasia Prostatism Quality of Life Randomized Controlled Trials as Topic Sulfonamides Tamsulosin Urological Agents

Adrenergic alpha-Antagonists/administration & dosage/*therapeutic use Cholinergic Antagonists/administration & dosage Drug Therapy Combination Humans *Lower Urinary Tract Symptoms Male Prostatic Hyperplasia/*diagnosis/*drug therapy Publication Bias Quality of Life Treatment Outcome

5-alpha Reductase Inhibitors/*adverse effects Drug Therapy Combination Ejaculation/drug effects Erectile Dysfunction/*chemically induced/drug therapy Finasteride Humans Libido/*drug effects Male Middle Aged Prostatic Hyperplasia/*drug therapy Randomized Controlled Trials as Topic *5α-Reductase Inhibitors *Erectile Dysfunction *Meta-Analysis *Sexual Dysfunction

Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Adrenergic alpha-Antagonists Dose-Response Relationship Drug Humans Male Middle Aged Prostatic Hyperplasia *Quality of Life Sulfonamides/*administration & dosage Tamsulosin Prostatic hyperplasia alpha blockers

Botulinum Toxins Type A/administration & dosage Humans Injections Male Neuromuscular Agents/administration & dosage Prostatic Hyperplasia/*drug therapy Treatment Outcome Benign prostatic hyperplasia Botulinum toxin Meta-analysis Placebo

Humans Immune Checkpoint Inhibitors/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms/drug therapy Proportional Hazards Models Eastern Cooperative Oncology Group Immune checkpoint inhibitor Performance status Urothelial carcinoma

Humans *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms/pathology *Urologic Neoplasms/drug therapy/pathology Antibodies Monoclonal/adverse effects

Humans *BCG Vaccine/adverse effects *Urinary Bladder Neoplasms/drug therapy BCG vaccine administration intravesical systematic review urinary bladder neoplasms

Humans *Adjuvants Immunologic/therapeutic use/adverse effects Administration Intravesical Neoplasm Recurrence Local/epidemiology *Urinary Bladder Neoplasms/pathology Drug Administration Schedule Bcg Cvnmi Desabastecimiento Dosis completa Dosis reducida Full dose Nmibc Reduced dose Shortage

Humans Photosensitizing Agents/therapeutic use Neoplasm Residual Neoplasm Recurrence Local/prevention & control *Photochemotherapy/methods Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/drug therapy/surgery/diagnosis Aminolevulinic Acid/therapeutic use Cystoscopy/methods Cystoscopy Fluorescent cystoscopy Hexaminolevulinate Meta-analysis Nonmuscle invasive bladder cancer Urinary bladder neoplasms conflicts of interest in the manuscript and during the submission process. This manuscript has not been published and is not under consideration for publication elsewhere.

Humans Mitomycin Gemcitabine Hematuria *Non-Muscle Invasive Bladder Neoplasms Deoxycytidine/therapeutic use Administration Intravesical *Urinary Bladder Neoplasms/drug therapy *Cystitis Chemical cystitis Cistitis química Cáncer de vejiga sin invasión muscular Gemcitabina intravesical Intravesical gemcitabine Intravesical mitomycin Mitomicina intravesical Non-muscle invasive bladder cancer Recurrence rates Tasas de recurrencia

Humans Mitomycin/therapeutic use Antibiotics Antineoplastic BCG Vaccine/therapeutic use *Non-Muscle Invasive Bladder Neoplasms Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Administration Intravesical Neoplasm Invasiveness Bladder cancer Device-assisted Emda Intravesical drug administration Nmibc

Humans Female *Carcinoma Transitional Cell/chemically induced/epidemiology/genetics DNA Adducts/adverse effects *Drugs Chinese Herbal/adverse effects Taiwan/epidemiology *Urinary Bladder Neoplasms Carcinogens *Kidney Neoplasms/chemically induced/epidemiology/genetics *Aristolochic Acids/adverse effects/analysis *Ureteral Neoplasms/chemically induced/epidemiology *Urinary Tract Aristolochia DNA adduct Mass spectrometry Nephropathy Renal pelvic cancer Ureteral cancer

*Carcinoma Transitional Cell/drug therapy Humans Organoids Precision Medicine *Urinary Bladder Neoplasms/drug therapy Urothelium/pathology Metastases Personalized medicine Stem cells Transurethral resection

Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/*pathology Female Humans Immune Checkpoint Inhibitors/*therapeutic use Liver Neoplasms/secondary Male Middle Aged Survival Analysis Urinary Bladder Neoplasms/*drug therapy/*pathology bladder cancer immune checkpoint inhibitors immunotherapy meta-analysis urothelial carcinoma

Cystoscopy Humans Narrow Band Imaging/methods Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/diagnostic imaging/drug therapy/surgery

Administration Intravesical Combined Modality Therapy Cystectomy/*methods Humans Neoplasm Recurrence Local/*epidemiology Network Meta-Analysis Randomized Controlled Trials as Topic Urethra Urinary Bladder Neoplasms/*diagnostic imaging/drug therapy/epidemiology/*surgery #BladderCancer #blcsm #uroonc blue-light cystoscopy hexaminolevulinic acid narrow band imaging non-muscle-invasive urothelial carcinoma photodynamic diagnosis single immediate intravesical chemotherapy

Humans Carboplatin/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms Carboplatin Cisplatin Immune checkpoint inhibitors Platinum-based chemotherapy Urothelial carcinoma

Cisplatin/adverse effects Humans *Immunotherapy/adverse effects/methods *Muscles/pathology *Neoadjuvant Therapy/adverse effects Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/pathology/therapy chemoimmunotherapy immunotherapy meta-analysis muscle-invasive bladder cancer (MIBC) neoadjuvant commercial or financial relationships that could be construed as a potential conflict of interest.